Loading...
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [(11)C]GSK2256098
BACKGROUND: GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expansion cohort within a phase I study, the safety, tol...
Na minha lista:
| Udgivet i: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6231205/ https://ncbi.nlm.nih.gov/pubmed/29788497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy078 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|